InstalabLoading...
InstalabLoading...
If you have unexplained joint pain, fatigue, rashes, dry eyes, or a family history of lupus or other autoimmune disease, this is the test that helps answer whether your immune system is starting to attack your own tissues. It is the standard entry point for evaluating systemic autoimmune disease and is required as a classification criterion for systemic lupus erythematosus.
The result is most useful when read in context. A positive result is common in healthy people, and a negative result does not always rule out autoimmune disease. The titer (how high the level is), the staining pattern, and what other autoantibodies are present together turn this from a screening number into a meaningful clinical signal.
ANA (antinuclear antibodies) are autoantibodies, mostly of the IgG class, that bind to components inside your cell nuclei such as DNA, histones (the proteins DNA wraps around), and other nuclear proteins. The standard test uses a method called indirect immunofluorescence on HEp-2 cells, which detects both the amount of antibody (reported as a titer like 1:80 or 1:320) and the staining pattern (homogeneous, speckled, nucleolar, centromere, and others).
The pattern matters because it points toward different diseases. A homogeneous or speckled pattern is most common in lupus. A centromere or nucleolar pattern points toward systemic sclerosis (a connective tissue disease that hardens skin and organs). The test reflects whether your immune system is producing antibodies against your own cells, but it does not by itself diagnose any specific disease.
In a large laboratory cohort, ANA was positive in 78.7% of people with systemic autoimmune rheumatic disease compared with 12.2% of healthy controls. Positivity was highest in mixed connective tissue disease (MCTD) at 92.3% and systemic lupus erythematosus (SLE) at 90.7%. A titer of 1:320 or higher carried a positive predictive value of 84% for systemic autoimmune rheumatic disease, meaning 84 out of 100 people with that level had one of these diseases.
Among people with lupus, certain ANA patterns track with more aggressive disease. Speckled patterns appeared in 52.1% and homogeneous in 35.2% of lupus cases. Peripheral, mixed, and speckled patterns were associated with higher anti-double-stranded DNA antibodies, higher antiphospholipid antibodies, and lower complement C4 (a protein that gets used up during active autoimmune inflammation), which together suggest a more active and harder-to-control disease pattern.
ANA is also a screening test for Sjögren's syndrome (which causes severe dry eyes and dry mouth), systemic sclerosis (which hardens skin and internal organs), and autoimmune hepatitis (immune attack on the liver). In primary biliary cirrhosis, a related autoimmune liver disease, the IgG3 subclass of ANA was associated with a more severe disease course.
In autoimmune hepatitis, diagnosis depends on combining ANA with elevated total IgG and liver enzyme abnormalities. ANA alone is rarely enough; specific patterns and additional autoantibodies refine the picture toward one disease versus another.
In a large population-based study of 205,632 people, ANA positivity was associated with increased all-cause mortality, and the increase was especially clear in people without a diagnosed rheumatologic condition. In another large study of 28,781 individuals without autoimmune disease, a high ANA titer was linked to higher rates of liver disorders and related metabolic complications.
In an older population (the Baltimore Longitudinal Study of Aging), ANA positivity was associated with higher odds of type 2 diabetes and multimorbidity (having multiple chronic conditions at once) in women but not in men. A separate cohort of 1,641 people found ANA positivity was associated with an increased risk of diffuse large B-cell lymphoma, a type of blood cancer.
What this means for you: a persistently positive ANA, even without a clear rheumatic diagnosis, is not always a benign finding. It is worth tracking and worth pairing with liver, metabolic, and inflammatory markers.
In a prospective cohort of 1,085 Japanese pregnant women, first-trimester ANA positivity was associated with an increased risk of preterm birth. A meta-analysis also identified ANA positivity as a significant risk factor for recurrent pregnancy loss, making it a reasonable test for women who have had multiple early miscarriages without a clear cause.
Two facts can both be true: a positive ANA carries real risk signals (mortality, autoimmune disease, pregnancy loss), and most people with a low-titer positive ANA do not have an autoimmune disease. The way to make sense of this is to think of ANA as a probability marker rather than a yes-or-no diagnosis. A low-titer positive in a healthy person with no symptoms is mostly noise. The same titer in someone with joint pain, dry eyes, or unexplained fatigue is a meaningful signal. And a high titer (1:320 or higher), especially with a specific pattern and additional autoantibodies, sharply raises the probability of disease in either context.
These thresholds come from indirect immunofluorescence on HEp-2 cells, which is the most common method but not the only one. Solid-phase assays (ELISA-style tests) report numerical units instead of titers and have different cutoffs. Compare your results within the same lab and method over time.
| Result | What It Suggests |
|---|---|
| Negative | No detectable autoantibodies against nuclear components. Does not fully rule out autoimmune disease, since some lupus patients are ANA-negative depending on the assay used. |
| Positive at 1:80 | Common in healthy adults. Low specificity. In one referral study, no titer below 1:160 led to a diagnosis of an ANA-associated rheumatic disease. |
| Positive at 1:160 | Threshold used in heart transplant cohorts and many clinical settings. Begins to raise probability of disease, especially with symptoms. |
| Positive at 1:320 or higher | High specificity. Positive predictive value of 84% for systemic autoimmune rheumatic disease in a large cohort. |
Source: Wei et al., Journal of Clinical Laboratory Analysis (2020); Abeles et al., American Journal of Medicine (2013).
A single ANA result is rarely enough to act on. Titers can rise and fall over time, and patterns can shift. In a Swedish cohort of lupus patients, a meaningful proportion lost ANA positivity over years of follow-up, while patterns tended to stay consistent. Repeat testing tells you whether your immune activation is escalating, stable, or quieting down.
If you are healthy with a low-titer positive result and no symptoms, recheck in 6 to 12 months. If your titer is rising, if you are developing symptoms, or if you are using this test to monitor treatment, retest every 3 to 6 months. Always compare results from the same lab using the same method, since assay variation can produce different titers and even different positivity calls on the same sample.
A positive ANA is the start of a workup, not the end. The next step is the ENA panel (extractable nuclear antigens), which tests for specific antibodies including anti-dsDNA, anti-Sm, anti-SSA/Ro, anti-SSB/La, anti-RNP, anti-Scl-70, and anti-centromere. Each one points toward a specific disease.
ANA can become positive in situations that are not true autoimmune disease.
ANA testing is most useful when there is real clinical suspicion of autoimmune disease, a family history of lupus or another connective tissue disease, unexplained recurrent miscarriages, or persistent symptoms like joint pain, fatigue, photosensitive rashes, or sicca symptoms (severe dry eyes and dry mouth). Broad screening of asymptomatic, low-risk people produces many positives that lead nowhere, but targeted use in higher-risk groups (women of childbearing age with symptoms, family members of people with lupus) can catch disease early enough to change its course.
Evidence-backed interventions that affect your Anti-Nuclear Antibodies IgG level
Anti-Nuclear Antibodies IgG is best interpreted alongside these tests.